Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Immunotherapy for frontline treatment of ALL: inotuzumab ozogamicin and blinatumomabПодробнее

Immunotherapy for frontline treatment of ALL: inotuzumab ozogamicin and blinatumomab

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicin

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicin

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?Подробнее

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?

Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVDПодробнее

Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVD

Inotuzumab as a potential treatment for elderly patients with ALLПодробнее

Inotuzumab as a potential treatment for elderly patients with ALL

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALLПодробнее

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALL

Side-effects of inotuzumab ozogamicinПодробнее

Side-effects of inotuzumab ozogamicin

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety resultsПодробнее

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety results